title: Pathological characteristics of BRCA-associated breast cancers in Hispanics.
abstract: The immunophenotype of BRCA-associated breast cancer has been studied in predominantly non-Hispanic whites (NHW). We evaluated the pathological characteristics of BRCA-associated invasive breast cancer in Hispanics. A case-control study was conducted on breast cancers from Hispanic and NHW women who enrolled in an IRB-approved registry and underwent BRCA gene analysis. BRCA negative controls (41 Hispanic, 39 NHW) were matched on age and ethnicity to BRCA positive cases (39 Hispanic, 35 NHW). A tissue array was constructed to characterize the expression of estrogen receptor (ER), progesterone receptor (PR), HER2, Ki-67 and p53 by immunohistochemistry. Mean age at diagnosis was 37.1 years (range 24-59) for Hispanics (80% with Mexican ancestry) and 40.1 years (range 21-63) for NHW (P = 0.03). Hispanic BRCA1 cases were more likely than BRCA negative controls to have tumors that were ER-negative (P < 0.001) and PR-negative (P = 0.001), had higher levels of Ki-67 (P = 0.001) and p53 expression, and lower levels of HER2 overexpression. When stratified by genes, there were no significant differences in expression of ER, Ki-67, HER2, and p53 by ethnicity among mutation carriers. However, a significantly higher proportion of BRCA-positive Hispanics had PR-negative tumors compared to BRCA-positive NHW (80 vs. 57%, OR = 2.9, 95% CI 1.0-8.1, P = 0.04). Hispanic BRCA-associated breast cancers were found to have the unique immunophenotype associated with BRCA mutations; however, there was a trend toward a difference in PR expression among Hispanic BRCA1 and BRCA2 cases. Additional research on the molecular mechanisms involved in the loss of PR in this population is warranted as it could have important implications for the treatment and prevention of breast cancer in Hispanics.
authors: Division of Clinical Cancer Genetics, City of Hope, Duarte, CA, 91010, USA.
authors: Veronica I
authors: VI
authors: Lagos-Jaramillo
authors: Michael F
authors: MF
authors: Press
authors: Charité N
authors: CN
authors: Ricker
authors: Louis
authors: L
authors: Dubeau
authors: Phuong L
authors: PL
authors: Mai
authors: Jeffrey N
authors: JN
authors: Weitzel
references: Cancer. 1995 Jul 15;76(2):268-74
references: 8625102
references: Clin Cancer Res. 2006 Aug 1;12(15):4614-8
references: 16899609
references: Cancer. 2003 Jan 1;97(1):134-47
references: 12491515
references: Clin Cancer Res. 2005 Sep 15;11(18):6598-607
references: 16166438
references: Lancet. 1997 Aug 30;350(9078):638-9
references: 9288052
references: J Natl Cancer Inst. 1994 May 4;86(9):705-12
references: 7908990
references: Cancer. 2007 May 1;109(9):1721-8
references: 17387718
references: Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1666-71
references: 16030099
references: Breast Cancer Res Treat. 2003 Sep;81(1):53-60
references: 14531497
references: J Clin Oncol. 2002 May 1;20(9):2310-8
references: 11981002
references: Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1534-8
references: 15941968
references: J Clin Oncol. 1992 Aug;10(8):1284-91
references: 1634918
references: Cancer Res. 1999 Apr 15;59(8):2011-7
references: 10213514
references: Lab Invest. 1990 Nov;63(5):722-4
references: 2232717
references: Clin Cancer Res. 2001 Jun;7(6):1739-42
references: 11410514
references: Cancer Epidemiol Biomarkers Prev. 1996 Nov;5(11):861-6
references: 8922292
references: Breast J. 2004 Sep-Oct;10(5):462-4
references: 15327507
references: J Clin Oncol. 2005 Oct 20;23(30):7721-35
references: 16234531
references: Clin Cancer Res. 1995 Oct;1(10):1203-8
references: 9815913
references: Cancer. 2001 Jul 1;92(1):37-45
references: 11443607
references: Clin Breast Cancer. 2005 Aug;6(3):240-6
references: 16137435
references: Cell Mol Biol (Noisy-le-grand). 2001 Sep;47(6):1025-32
references: 11785652
references: J Natl Cancer Inst. 1998 Aug 5;90(15):1138-45
references: 9701363
references: Lancet. 1995 Jun 10;345(8963):1503
references: 7769911
references: Breast Cancer Res Treat. 2005 Mar;90(1):5-14
references: 15770521
references: J Clin Oncol. 2003 May 15;21(10):1973-9
references: 12743151
references: Cancer. 1996 Apr 15;77(8):1465-71
references: 8608530
references: Cancer. 2000 Jan 1;88(1):114-23
references: 10618613
references: Am J Pathol. 2000 Jan;156(1):183-91
references: 10623666
references: Clin Cancer Res. 2001 Jul;7(7):1937-45
references: 11448907
references: Lancet. 1998 Jan 31;351(9099):316-21
references: 9652611
references: Cancer. 1998 Jul 15;83(2):310-9
references: 9669814
references: Steroids. 2002 Aug;67(9):799-813
references: 12123792
references: Cancer Res. 1986 Apr;46(4 Pt 2):2117-20
references: 3948183
references: J Clin Oncol. 2002 Jul 15;20(14):3095-105
references: 12118023
references: Int J Gynecol Pathol. 1999 Jan;18(1):29-41
references: 9891239
references: Cancer Res. 1998 Apr 15;58(8):1588-92
references: 9563465
references: Cancer. 2011 Aug 15;117(16):3658-69
references: 21387260
references: J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5
references: 14519755
references: Appl Immunohistochem Mol Morphol. 2002 Jun;10(2):183-6
references: 12051639
references: Arch Intern Med. 2003 Jan 13;163(1):49-56
references: 12523916
references: J Natl Cancer Inst. 2011 Feb 2;103(3):250-63
references: 21191117
references: Cancer Res. 2000 May 15;60(10):2716-22
references: 10825146
references: Clin Cancer Res. 2004 Mar 15;10(6):2029-34
references: 15041722
references: Am J Surg Pathol. 2007 Jan;31(1):121-8
references: 17197928
references: Crit Rev Oncol Hematol. 2006 Jul;59(1):27-39
references: 16530420